Daryl Gaugler - May 4, 2022 Form 3 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role: Chief Operating Officer
Signature: /s/ Kristen Williams, Attorney-in-Fact
Stock symbol: PCRX
Transactions as of: May 4, 2022
Transactions value $: $0
Form type: 3
Date filed: 5/11/2022, 04:15 PM
Next filing: Jun 8, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	PCRX	Common Stock						12.6K	May 4, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	PCRX	Stock Option (Right to Buy)							May 4, 2022	Common Stock	15K	$60.96	Direct	F2
holding	PCRX	Stock Option (Right to Buy)							May 4, 2022	Common Stock	20K	$52.37	Direct	F3
holding	PCRX	Stock Option (Right to Buy)							May 4, 2022	Common Stock	10K	$47.65	Direct	F3
holding	PCRX	Stock Option (Right to Buy)							May 4, 2022	Common Stock	20K	$42.54	Direct	F3
holding	PCRX	Stock Option (Right to Buy)							May 4, 2022	Common Stock	10K	$34.00	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 12,000 unvested restricted stock units. The unvested restricted stock units vest as follows: (i) 6,000 restricted stock units that vest in four equal annual installments on June 3, 2022, June 3, 2023, June 3, 2024 and June 3, 2025, and (ii) 6,000 restricted stock units that vest in three equal annual installments on June 3, 2022, June 3, 2023 and June 3, 2024, in each case, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2	The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
F3	The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
F4	The stock option vested in equal monthly installments over one year following the grant date, provided that the reporting person remained in continuous service with the issuer as of each vesting date.